SanegeneBio, a clinical-stage biotechnology company focused on developing best-in-class RNAi medicines, announced that it will present the latest preclinical data for its LEAD™ platform-derived candidate SGB-ALK7 at the American Diabetes Association (ADA) 85th Scientific Sessions, held from June 20–23, 2025, at McCormick Place Convention Center in Chicago. A single subcutaneous dose of SGB-ALK7 in primates results in >90% silencing of its mRNA target in adipose tissue, with long duration of action and exquisite selectivity.
This late-breaking presentation will be displayed in the Poster Hall (Location: 23-A Obesity—Animal) throughout the three-day session (Saturday to Monday). Additionally, Dr. Peng Zhang (Principal Scientist, Biology, SanegeneBio) will be available for discussions at the poster board on June 22, 2025 (Sunday) from 12:30 PM to 1:30 PM.
We invite all attendees to visit our poster and join the conversation! #ADA2025
